Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Fennec Pharmaceuticals Ord Shs T.FRX

Alternate Symbol(s):  FENC

Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on its product candidate PEDMARK. It sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is a Food and Drug Administration approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. It is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase 3 clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. It has established Fennec HEARS, a single source program designed to connect PEDMARK patients.


TSX:FRX - Post by User

Post by Brinkleyon Jun 09, 2017 6:46am
300 Views
Post# 26343766

Financing with new investor

Financing with new investorI wasn't sure I liked the dilution at first but then I looked into Venbio select advisor.

got this from their website.

"We focus principally in securities of publicly traded biotechnology companies, and selectively in late-stage private thereputic companies often in advance of an exit. ( M&A,IPO)"


https://www.venbio.com/pubmarkets.html

so then I thought about the positives. 

- enough cash to get to approval, this will help negotiations if Fennec decides to partner or sell
- Venbio's experience and support to exit will be very valuable
- possibility of listing on Nasdaq now that the criteria is satisfied
- increased visibility should help the stock price.  

Rosty has done a fantastic job of keeping the share count down and not diluting the shareholders. I think all in all this financing is very positive. 

Any thoughts?

i feel like I have been talking to myself on this board lately 
Bullboard Posts